Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Kereiakes DJ, et al. Among authors: teirstein p. Am Heart J. 2002 Oct;144(4):615-24. doi: 10.1067/mhj.2002.124405. Am Heart J. 2002. PMID: 12360156 Review.
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Lincoff AM, et al. Among authors: teirstein ps. Am J Cardiol. 1997 Feb 1;79(3):286-91. doi: 10.1016/s0002-9149(96)00749-7. Am J Cardiol. 1997. PMID: 9036746 Clinical Trial.
Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996.
Ellis SG, Tamai H, Nobuyoshi M, Kosuga K, Colombo A, Holmes DR, Macaya C, Grines CL, Whitlow PL, White HJ, Moses J, Teirstein PS, Serruys PW, Bittl JA, Mooney MR, Shimshak TM, Block PC, Erbel R. Ellis SG, et al. Among authors: teirstein ps. Circulation. 1997 Dec 2;96(11):3867-72. doi: 10.1161/01.cir.96.11.3867. Circulation. 1997. PMID: 9403609
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Steinhubl SR, et al. Among authors: teirstein ps. Circulation. 2001 May 29;103(21):2572-8. doi: 10.1161/01.cir.103.21.2572. Circulation. 2001. PMID: 11382726 Clinical Trial.
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.
Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. Vaduganathan M, et al. J Am Coll Cardiol. 2017 Jan 17;69(2):176-185. doi: 10.1016/j.jacc.2016.10.055. J Am Coll Cardiol. 2017. PMID: 28081827 Free article. Clinical Trial.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Popma JJ, et al. Among authors: teirstein ps. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16. N Engl J Med. 2019. PMID: 30883053 Clinical Trial.
239 results